title: Cardiac inotropes: current agents and future directions.
abstract: Intrinsic inotropic stimulation of the heart is central to the regulation of cardiovascular function, and exogenous inotropic therapies have been used clinically for decades. Unfortunately, current inotropic drugs have consistently failed to show beneficial effects beyond short-term haemodynamic improvement in patients with heart failure. To address these limitations, new agents targeting novel mechanisms are being developed: (i) istaroxime has been developed as a non-glycoside inhibitor of the sodium-potassium-ATPase with additional stimulatory effects on the sarcoplasmic reticulum calcium pump (SERCA) and has shown lusitropic and inotropic properties in experimental and early clinical studies; (ii) from a mechanistic point of view, the cardiac myosin activators, directly activating the acto-myosin cross-bridges, are most appealing with improved cardiac performance in both animal and early clinical studies; (iii) gene therapy approaches have been successfully employed to increase myocardial SERCA2a; (iv) nitroxyl donors have been developed and have shown evidence of positive lusitropic and inotropic, as well as potent vasodilatory effects in early animal studies; (v) the ryanodine receptor stabilizers reduce pathological leak of calcium from the sarcoplasmic reticulum with initial promising pre-clinical results; and finally, (vi) metabolic energy modulation may represent a promising means to improve contractile performance of the heart. There is an urgent clinical need for agents that improve cardiac performance with a favourable safety profile. These current novel approaches to improving cardiac function provide the hope that such agents may soon be available.
authors.affiliation: Department of Cardiology and Pneumology, University Medical Center, Heart Research Center Göttingen, Robert-Koch-Strasse 40, 37075 Göttingen, Germany. hasenfus@med.uni-goettingen.de
authors.forename: Gerd
authors.initials: G
authors.lastname: Hasenfuss
authors.forename: John R
authors.initials: JR
authors.lastname: Teerlink
mesh_terms: D020746:Calcium Channels, L-Type / Q000187:drug effects; D024722:Cardiac Myosins / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D015195:Drug Design; D004734:Energy Metabolism / Q000187:drug effects; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends; D006329:Heart Conduction System / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D012519:Sarcoplasmic Reticulum / Q000187:drug effects; D013678:Technology, Pharmaceutical / Q000639:trends*
chemical_list: D020746:Calcium Channels, L-Type; D002316:Cardiotonic Agents; D024722:Cardiac Myosins